Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Covington
McKesson
US Army
Mallinckrodt
Chinese Patent Office
Johnson and Johnson
QuintilesIMS
US Department of Justice
Farmers Insurance
McKinsey

Generated: December 12, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,501,225

« Back to Dashboard

Which drugs does patent 8,501,225 protect, and when does it expire?


Patent 8,501,225 protects VASCEPA and is included in one NDA. There have been two Paragraph IV challenges on Vascepa.

This patent has twenty-two patent family members in fifteen countries.

Summary for Patent: 8,501,225

Title:Stable pharmaceutical composition and methods of using same
Abstract: The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases.
Inventor(s): Manku; Mehar (England, GB), Osterloh; Ian (Kent, GB), Wicker; Pierre (Mystic, CT), Braeckman; Rene (Richboro, PA), Soni; Paresh (Mystic, CT)
Assignee: Amarin Pharmaceuticals Ireland Limited (Dublin, IE)
Application Number:13/614,146
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Amarin PharmsVASCEPAicosapent ethylCAPSULE;ORAL202057-001Jul 26, 2012RXYesYes► Subscribe► Subscribe► SubscribeMETHOD OF REDUCING TG LEVELS IN PATIENT SUFFERING FROM SEVERE HYPERTRIGLYCERIDEMIA
Amarin PharmsVASCEPAicosapent ethylCAPSULE;ORAL202057-002Feb 16, 2017RXYesNo► Subscribe► Subscribe► SubscribeMETHOD OF REDUCING TG LEVELS IN PATIENT SUFFERING FROM SEVERE HYPERTRIGLYCERIDEMIA
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,501,225

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,138,415Stable pharmaceutical composition and methods of using same► Subscribe
8,617,593Stable pharmaceutical composition and methods of using same► Subscribe
9,060,983Stable pharmaceutical composition and methods of using same► Subscribe
8,703,185Stable pharmaceutical composition and methods of using same► Subscribe
8,298,554Stable pharmaceutical composition and methods of using same► Subscribe
8,617,594Stable pharmaceutical composition and methods of using same► Subscribe
9,585,856Stable pharmaceutical composition and methods of using same► Subscribe
8,709,475Stable pharmaceutical composition and methods of using same► Subscribe
8,623,406Stable pharmaceutical composition and methods of using same► Subscribe
8,613,945Stable pharmaceutical composition and methods of using same► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,501,225

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
New Zealand627238► Subscribe
Russian Federation2011148362► Subscribe
Russian Federation2538691► Subscribe
Russian Federation2014131716► Subscribe
Singapore175389► Subscribe
Singapore10201605794P► Subscribe
European Patent Office2424356► Subscribe
Hong Kong1165944► Subscribe
Hong Kong1210717► Subscribe
South Korea20120000109► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Accenture
Harvard Business School
Cantor Fitzgerald
McKesson
Baxter
Cipla
Johnson and Johnson
Mallinckrodt
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot